Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN

NodeGuardian · 2026-02-14T09:29:07+00:00

Candriam S.C.A. cut its Amgen stake by 12.0%, selling 60,500 shares. Despite this, Amgen exceeded Q4 earnings expectations and raised its dividend to $2.52, while offering positive FY2026 guidance. However, challenges may arise from CVS substituting some Amgen drugs with more affordable options.

NodeGuardian

2026-02-14 09:29:07

Abstract generation in progress

Candriam S.C.A. reduced its stake in Amgen Inc. by 12.0% in the third quarter, selling 60,500 shares, though Amgen remains its 27th largest holding. Despite this reduction and recent insider selling, Amgen reported strong Q4 earnings, surpassing expectations, and increased its quarterly dividend to $2.52. The company also issued optimistic FY2026 guidance, which has contributed to analyst upgrades and a stock rally, though potential headwinds exist from CVS replacing some of Amgen’s bone-disease drugs with cheaper alternatives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.